This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Retail Sales Hotter at +0.7%; JNJ, BAC, GS All Beat in Q3
by Mark Vickery
Retail Sales infer a consumer willing to spend, and the outlook for Q3 GDP is likely up somewhat on this news.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Pop on Bargain Hunting, Stronger Economy
by Mark Vickery
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Will Big Stocks Make Big Headlines? Global Week Ahead
by John Blank
This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.
Wall Street Waits for Big Earnings Results
by Zacks Equity Research
Wall Street Waits for Big Earnings Results.
Empire State Less Bad than Expected; SCHW Mixed in Q3
by Mark Vickery
We've only seen four months in positive territory on Empire State manufacturing year to date, the highest being +10.8 in April.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
by Zacks Equity Research
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates
by Kinjel Shah
Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.
Dow ETF in Focus Ahead of Q3 Earnings
by Sweta Killa
With some of the blue-chip companies having reasonable chances of coming up with an earnings surprise, investors should closely monitor the movement of the Dow ETF and grab any opportunity that arises from a surge in any of the 30 stocks.
Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
by Zacks Equity Research
J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
by Zacks Equity Research
Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $155.15 in the latest trading session, marking a -0.39% move from the prior day.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
by Zacks Equity Research
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J
by Zacks Equity Research
AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs
by Kinjel Shah
The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.